Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Feiba Global Outcome Study (FEIBA-GO): Long-Term Real World Data on Apcc (Feiba R ) in Patients with Inhibitors. First Demographic Data

Ana Rosa Cid, MD, Carmen Escuriola, MD, Cedric R. Hermans, MD PhD MRCP, Pal André Holme, PhD MD, Claude Negrier, MD, Savita Rangarajan, Angiola Rocino, Jerzy Windyga, MD, Alessandro Gringeri, MD MSc, Roberto Crea, DVM, MSc

Blood (2016) 128 (22): 5038.

https://doi.org/10.1182/blood.V128.22.5038.5038

Published: 2016

Journal Articles

The bleeding score predicts clinical outcomes and replacement therapy in adults with von Willebrand disease

Augusto B. Federici, Paolo Bucciarelli, Giancarlo Castaman, Maria G. Mazzucconi, Massimo Morfini, Angiola Rocino, Mario Schiavoni, Flora Peyvandi, Francesco Rodeghiero, Pier Mannuccio Mannucci

Blood (2014) 123 (26): 4037–4044.

https://doi.org/10.1182/blood-2014-02-557264

Published: 2014

Journal Articles

Source and Purity of Factor VIII Products As Risk Factors for Inhibitor Development In Previously Untreated Patients with Severe Hemophilia A

Maria Elisa Mancuso, MD, PhD, Pier Mannuccio Mannucci, MD, Angiola Rocino, MD, Isabella Garagiola, Annarita Tagliaferri, Elena Santagostino, MD, PhD

Blood (2011) 118 (21): 25.

https://doi.org/10.1182/blood.V118.21.25.25

Published: 2011

Journal Articles

Prophylactic Dosing of Anti-Inhibitor Coagulant Complex (FEIBA) Reduces Bleeding Frequency In Hemophilia A Patients with Inhibitors: Results of the Pro-FEIBA Study

Cindy A. Leissinger, MD, Eric Berntorp, MD, Chiara Biasioli, MD, Shannon Carpenter, MD, MS, Hyejin Jo, MS, Kaan Kavakli, MD, Claude Negrier, MD, Angiola Rocino, MD, Jerzy Windyga, MD, Bulent Zulfikar, MD, Alessandro Gringeri, MD

Blood (2010) 116 (21): 720.

https://doi.org/10.1182/blood.V116.21.720.720

Published: 2010

Journal Articles

Prevalence and Determinants of Bleeding in Severe Von Willebrand Disease Type 3: Results of Retro/Prospective Studies in a Cohort of 105/52 Italian Patients.

Augusto B. Federici, Paolo Bucciarelli, MD, Alfonso Iorio, Giancarlo Castaman, Maria Gabriella Mazzucconi, Massimo Morfini, Angiola Rocino, MD, Pier M. Mannucci, MD

Blood (2009) 114 (22): 3494.

https://doi.org/10.1182/blood.V114.22.3494.3494

Published: 2009

Journal Articles

Type of Factor VIII Product as Inhibitor Risk Factor in Patients with Severe Hemophilia A and Null Mutations.

Maria Elisa Mancuso, MD, PhD, Pier Mannuccio Mannucci, MD, Angiola Rocino, MD, Isabella Garagiola, PhD, AnnaRita Tagliaferri, MD, Maurizio Margaglione, MD, Elena Santagostino, MD, PhD

Blood (2009) 114 (22): 3500.

https://doi.org/10.1182/blood.V114.22.3500.3500

Published: 2009

Journal Articles

Incidence and Determinants of Bleeding in Different Types of von Willebrand Disease: Results of the First Prospective Multicenter Study on 814 Italian Patients.

Augusto B. Federici, MD, Paolo Bucciarelli, MD, Giancarlo Castaman, MD, Maria G. Mazzucconi, MD, Massimo Morfini, MD, Angiola Rocino, MD, Mario Schiavoni, MD, Francesco Rodeghiero, MD, Pier M. Mannucci, MD

Blood (2007) 110 (11): 713.

https://doi.org/10.1182/blood.V110.11.713.713

Published: 2007

Journal Articles

Cardiotoxicity and Treatment Efficacy of Not Pegilated Liposomal Doxorubicin in Haematological Malignancies: Our Experience.

Alfredo Gagliardi, MD, Maria Lucia Boffa, MD, Gaetana Capobianco, MD, Concetta Cotarelli, BD, Donatella De Blasi, MD, Lucia Liguori, MD, Ruggiero Orlando, MD, Angiola Rocino, MD, Maria Maddalena Spiezia, MD, Luigi Ziello, MD, Eustachio Miraglia, MD

Blood (2007) 110 (11): 4836.

https://doi.org/10.1182/blood.V110.11.4836.4836

Published: 2007

Journal Articles

A Randomized Crossover Study of High- and Standard-Dose Recombinant Factor VIIa for Treatment of Hemarthroses in Hemophiliacs with Inhibitors.

Elena Santagostino, MD, PhD, Maria E. Mancuso, MD, Angiola Rocino, MD, Giacomo Mancuso, MD, Francesco A. Scaraggi, MD, Massimo Morfini, MD, Filomena Daniele, MD, Giovanni Barillari, MD, Pier M. Mannucci, MD

Blood (2005) 106 (11): 323.

https://doi.org/10.1182/blood.V106.11.323.323

Published: 2005

Journal Articles

High Efficacy of Combination Therapy with Pegylated Interferon and Ribavirin in Hemophiliacs with Chronic Hepatitis C.

Maria E. Mancuso, MD, Elena Santagostino, MD, PhD, Maria G. Rumi, MD, Silvia Linari, MD, Antonio Coppola, MD, Angiola Rocino, MD, Alfonso Iorio, MD, Alfredo Dragani, MD, Giovanni Barillari, MD, Giuseppe Tagariello, MD, Roberto Nicolin, MD, Massimo Colombo, MD, Pier M. Mannucci, MD

Blood (2005) 106 (11): 3219.

https://doi.org/10.1182/blood.V106.11.3219.3219

Published: 2005

Journal Articles

Impact of Early Factor VIII Exposure, Prophylaxis and Prenatal/Perinatal Events on Inhibitor Risk in Children with Hemophilia A: A Case-Control Study.

Elena Santagostino, MD, PhD, Angiola Rocino, MD, Maria E. Mancuso, MD, Maria G. Mazzucconi, MD, Giacomo Mancuso, MD, Maria Messina, MD, Annarita Tagliaferri, MD, Matteo Luciani, MD, Elio Boeri, MD, Pier M. Mannucci, MD

Blood (2004) 104 (11): 37.

https://doi.org/10.1182/blood.V104.11.37.37

Published: 2004

Journal Articles

A 6-month versus a 12-month surveillance for hepatocellular carcinoma in 559 hemophiliacs infected with the hepatitis C virus

Elena Santagostino, Massimo Colombo, Monica Rivi, Maria Grazia Rumi, Angiola Rocino, Silvia Linari, Pier Mannuccio Mannucci, for the the Study Group of the Association of Italian Hemophilia Centers

Blood (2003) 102 (1): 78–82.

https://doi.org/10.1182/blood-2002-10-3310

Published: 2003

Journal Articles

Residual factor VII activity and different hemorrhagic phenotypes in CRM + factor VII deficiencies (Gly331Ser and Gly283Ser)

Mirko Pinotti, Daniela Etro, Debora Bindini, Maria Luisa Papa, Giuseppina Rodorigo, Angiola Rocino, Guglielmo Mariani, Nicola Ciavarella, Francesco Bernardi

Blood (2002) 99 (4): 1495–1497.

https://doi.org/10.1182/blood.V99.4.1495

Published: 2002

NARROW

Feiba Global Outcome Study (FEIBA-GO): Long-Term Real World Data on Apcc (Feiba R ) in Patients with Inhibitors. First Demographic Data

The bleeding score predicts clinical outcomes and replacement therapy in adults with von Willebrand disease

Source and Purity of Factor VIII Products As Risk Factors for Inhibitor Development In Previously Untreated Patients with Severe Hemophilia A

Prophylactic Dosing of Anti-Inhibitor Coagulant Complex (FEIBA) Reduces Bleeding Frequency In Hemophilia A Patients with Inhibitors: Results of the Pro-FEIBA Study

Prevalence and Determinants of Bleeding in Severe Von Willebrand Disease Type 3: Results of Retro/Prospective Studies in a Cohort of 105/52 Italian Patients.

Type of Factor VIII Product as Inhibitor Risk Factor in Patients with Severe Hemophilia A and Null Mutations.

Incidence and Determinants of Bleeding in Different Types of von Willebrand Disease: Results of the First Prospective Multicenter Study on 814 Italian Patients.

Cardiotoxicity and Treatment Efficacy of Not Pegilated Liposomal Doxorubicin in Haematological Malignancies: Our Experience.

A Randomized Crossover Study of High- and Standard-Dose Recombinant Factor VIIa for Treatment of Hemarthroses in Hemophiliacs with Inhibitors.

High Efficacy of Combination Therapy with Pegylated Interferon and Ribavirin in Hemophiliacs with Chronic Hepatitis C.

Impact of Early Factor VIII Exposure, Prophylaxis and Prenatal/Perinatal Events on Inhibitor Risk in Children with Hemophilia A: A Case-Control Study.

A 6-month versus a 12-month surveillance for hepatocellular carcinoma in 559 hemophiliacs infected with the hepatitis C virus

Residual factor VII activity and different hemorrhagic phenotypes in CRM + factor VII deficiencies (Gly331Ser and Gly283Ser)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only